LGND - Earnings announcements

First quarter performance driven by strong year-over-year royalty revenue growth of 56% Reaffirms Previously Raised 2026 Full-Year Financial Guidance Reflecting Anticipated Partial-Year Contribution from Pending XOMA Royalty Acquisition Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2026, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss the results and answer questions. "The first few months of 2026 have al

Transaction expands Ligand's royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand's long-term compounding growth, adding a complementary portfolio across development stages, therapeutic areas, and modalities to broaden patient access and improve lives Acquisition is expected to be immediately accretive to Ligand adjusted EPS; Ligand increases 2026 adjusted EPS guidance to $8.50-$9.501 and expects the transaction to be accretive by $1.50 per share to adjusted EPS in 20272 Ligand to hold investor call at 8:00 a.m. ET today JUPITER, Fla. and EMERYVILLE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporate

JUPITER, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026. The company will hold a conference call beginning at 8:30 a.m. Eastern time to discuss the results and provide a general business update. Conference Call and Webcast Information   Date:  Thursday, May 7, 2026   Time: 8:30 a.m. Eastern time   Conference Call: United States (Local): +1 (585) 542-9983 United States (Toll-Free): +1 (833) 461-5787 International: Global Dial-in NumbersMeeting ID: 304603090   Webcast: Live and replay webcasts of the call are available here.    About LigandLigand is a

Robust financial performance driven by full year 2025 royalty revenue growth of 48% Reiterating 2026 financial guidance of $245-$285 million in revenues and adjusted earnings per diluted share1 of $8.00-$9.00 Conference call and webcast at 8:30 a.m. Eastern time today JUPITER, Fla., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and twelve months ended December 31, 2025, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today beginning at 8:30 a.m. Eastern time to discuss this announcement and answer questions. "We delivered strong fourth q

JUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. The company will hold a conference call beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast Information Date: Thursday, February 26, 2026  Time: 8:30 AM Eastern Time  Conference Call:(800) 715-9871 (U.S. & Canada)(646) 307-1963 (International)Conference ID 3661098  Webcast:Live and replay webcasts of the call are available here. About Ligand PharmaceuticalsLigand is a biopharmaceutical company enabling scienti

JUPITER, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025. The company will hold a conference call beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast Information Date:Thursday, November 6, 2025  Time:8:30 AM Eastern Time  Conference Call:(800) 715-9871 (U.S. & Canada)(646) 307-1963 (International)Conference ID 3661098  Webcast:Live and replay webcasts of the call are available here.   About Ligand PharmaceuticalsLigand is a biopharmaceutical company enabling scientific advancement th

JUPITER, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025. The company will hold a conference call beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast Information Date: Thursday, August 7, 2025  Time: 8:30 AM Eastern Time  Conference Call:(800) 715-9871 (U.S. & Canada)(646) 307-1963 (International)Conference ID 3661098  Webcast:Live and replay webcasts of the call are available here.   About Ligand PharmaceuticalsLigand is a biopharmaceutical company enabling scientific advancement thr

First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Creek Biosciences Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share of $6.00-$6.251 Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2025, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8

JUPITER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report first quarter 2025 financial results before the opening of the U.S. financial markets on Thursday, May 8, 2025. The company will hold a conference call that same day beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast InformationDate: Thursday, May 8, 2025   Time: 8:30 AM Eastern Time   Conference Call: (800) 715-9871 (U.S. & Canada)  (646) 307-1963 (International)  Conference ID 3661098   Webcast: Live and replay webcasts of the call are available here.    About Ligand PharmaceuticalsLiga

Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare-dedicated investors, completed transformation to a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic skin diseases Top-line results from SELVA, a Phase 3 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs), on track for the first quarter of 2026 Top-line results from TOIVA, a Phase 2 single-arm, baseline-controlled trial evaluating QTORIN™ rapamycin for the treatment of

Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share1 of $6.00-$6.25 Conference call and webcast at 8:30 a.m. Eastern time today JUPITER, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and twelve months ended December 31, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today beginning at 8:30 a.m. Eastern time to discuss this announcement and answer questions. "We achieved significant reve

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report fourth quarter and full year 2024 financial results before the opening of the U.S. financial markets on Thursday, February 27, 2025. The company will hold a conference call that same day beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast Information Date: Thursday, February 27, 2025   Time: 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time)   Conference Call: (800) 715-9871 (U.S. & Canada) (646) 307-1963 (International) Conference ID is 8755336   Webcast: Live and r

Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Easter

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report third quarter 2024 financial results before the opening of the U.S. financial markets on Thursday, November 7, 2024. The company will hold a conference call that same day beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast Information Date: Thursday, November 7, 2024     Time: 8:30 a.m. ET (5:30 a.m. PT)     Conference Call: (888) 596-4144 (U.S. & Canada)   (646) 968-2525 (International)   Conference ID is 8755336     Webcast: Live and replay webcasts of t

Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti

Proposed merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for serious, rare genetic skin diseases for which there are no FDA-approved therapiesCombined company is expected to have approximately $80.5 million of cash and cash equivalents at closing, including approximately $78.9 million from an oversubscribed private financing with participation from a syndicate of leading healthcare-dedicated investors, which is expected to provide cash runway into the second half of 2027Anticipated cash and cash equivalents are expected to fund combined company through multiple clinical trial milestones, including pivotal P

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report second quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, August 6, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update. Conference Call and Webcast Information Date: Tuesday, August 6, 2024 Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) Conference Call: (800) 715-9871 (U.S. & Canada) (646) 307-1963 (International) Conference ID is 8755336 Webcast: Live and replay webcasts of the call are avail

Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2024, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We are pleased to report another quarter of strong financial results driven by the performance of our commercial royalty portfolio. Simultaneously, we continue to build our portfolio of development stage royalty assets to deliver future growth," said Todd Davis, CEO of Ligand. "We continue to originate a robust pipe

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report first quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, May 7, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update. Conference Call and Webcast Information Date: Tuesday, May 7, 2024 Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) Conference Call: (800) 715-9871 (U.S. & Canada)   (646) 307-1963 (International)   Conference ID is 8755336 Webcast: Live and replay webcasts of the c

Conference Call and Webcast at 8:30 a.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and twelve months ended December 31, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call and webcast today beginning at 8:30 a.m. Eastern time to discuss this announcement and answer questions. "2023 was a transformative year for Ligand, both operationally and financially. We refocused the company to be a lean-infrastructure, high-margin business," said Todd Davis, CEO of Ligand. "We enhanced our deal making capabilities with the strengthening of our senior team and opening of

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report full year and fourth quarter 2023 financial results before the opening of the U.S. financial markets on Tuesday, February 27, 2024, and will hold a conference call at 8:30 a.m. Eastern Time that same day to discuss financial results and provide a general business update. Conference Call and Webcast Information Date:   Tuesday, February 27, 2024 Time:   8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) Conference Call:   (800) 715-9871 (North America toll-free number)     (647) 932-3411 (International number outside Canada; toll app

Raising 2023 Guidance Investor and Analyst Day to be held on Tuesday December 12th in New York City Conference call begins at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We're pleased to report another quarter of strong financial results and we are now actively executing on our investment strategy as evidenced by the recent Tolerance, Ovid, Novan and Primrose transact

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) will report third quarter 2023 financial results after the close of the U.S. financial markets on Wednesday, November 8, 2023, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update. Conference Call and Webcast Information Date:   Wednesday, November 8, 2023 Time:   4:30 p.m. Eastern time (1:30 p.m. Pacific time) Conference Call:   (888) 350-3452 (U.S. toll-free number)     1 (646) 960-0369 (ex-U.S. toll dial-in number)     Conference ID is 6501694 Webcas

Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three and six months ended June 30, 2023, and provided operating and partner program updates. "Our business continued to grow and perform well during the second quarter with advancements in business development and progress across partner programs. The addition of four new partners during the quarter, including Merck & Co. and Neurocrine Biosciences, highlights the relevance and robustness of our technology platform. Existing partners made progress with two new programs entering the clinic and the total number of active programs increased to 305," said M

Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "We are pleased to report continued momentum across our portfolio of partnered assets, with multiple positive developments for our commercial and pipeline products," said Todd Davis, CEO of Ligand. "Ligand has a strong balance sheet with $219 million in cash, and, after a recent paydown of convertible notes, w

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) will report second quarter 2023 financial results after the close of the U.S. financial markets on Tuesday, August 8, 2023, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update. Speakers on the call will include Ligand's CEO Todd Davis, President and COO Matt Korenberg, and CFO Tavo Espinoza. Conference Call and Webcast Information Date: Tuesday, August 8, 2023 Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time) Conference Call: (888) 350-3452 (U.S. toll-free number)   1 (646) 960-0369 (ex-U.S. tol

Conference Call with Slides Begins at 8:30 a.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three months ended March 31, 2023, and provided operating and partner program updates. "Our first quarter performance is a strong start to the year. We reached 301 active programs, with 27 in clinical development or approved for commercialization as our growing portfolio of partner programs continued to advance," said Matt Foehr, Chief Executive Officer of OmniAb, Inc. "Innovating our technologies is part of our strategy, and we are proud to introduce OmniDeep™ at next week's PEGS Protein Engineering Conference and Expo in Boston. OmniDeep is a suite of

2023 Financial Guidance Raised Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2023 is off to a strong start with $44.0 million in first quarter revenues driven by the continued growth of our royalty revenue and the approval milestone from Travere's FILSPARI for the treatment of IgA nephropathy," said Todd Davis, CEO of Ligand. "We have several partner catalyst

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) will report first quarter 2023 financial results after the close of the U.S. financial markets on Thursday, May 4, 2023, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update. Speakers on the call will include Ligand's CEO Todd Davis, President and COO Matt Korenberg, and CFO Tavo Espinoza. Conference Call and Webcast Information Date: Thursday, May 4, 2023 Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time) Conference Call: (888) 350-3452 (U.S. toll-free number)   1 (646) 960-0369 (ex-U.S. toll dial-in

Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three and 12 months ended December 31, 2022, and provided operating and partner program updates. "Following the closing of the spin-off and business combination transactions last November, OmniAb is well-positioned for continued growth by offering cutting-edge antibody discovery platforms and complementary technologies," said Matt Foehr, Chief Executive Officer of OmniAb. "Leveraging a rich heritage of innovations designed to facilitate the discovery of novel therapeutics including those targeting ion channels and transporters, OmniAb is at the forefront o

2023 Financial Guidance Raised Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and 12 months ended December 31, 2022, and provided an operating forecast and business updates. These financial results are presented on a continued operations basis as OmniAb was spun out on November 1, 2022 and is reported as discontinued operations. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2022 was a transformative year for Ligand, both operationally and financially. Following Ligand's spin out of OmniAb, we

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) will report fourth quarter 2022 financial results after the close of the U.S. financial markets on Wednesday, February 22, 2023 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will include Ligand's CEO Todd Davis, President and COO Matt Korenberg and CFO Tavo Espinoza. Conference Call and Webcast Information What: Ligand conference call to discuss financial results and provide general business updates     Date: Wednesday, February 22, 2023     Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)     Conference Call: Dial (888) 350-

Increased 2022 Financial Guidance Analyst and Investor Day to be Held on Tuesday December 13 in New York City Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2022 and provided operating and program updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "This quarter was focused on one of the most transformative transactions in Ligand's history, the spin-off of our OmniAb antibody discovery business. I am excited for what lies ahead for Ligand and OmniAb as b

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) will report third quarter 2022 financial results after the close of the U.S. financial markets on Monday, November 7, 2022 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will include Ligand's CEO John Higgins, President and COO Matt Korenberg and CFO Tavo Espinoza. Conference Call and Webcast Information What: Ligand conference call to discuss financial results and provide general business updates   Date: Monday, November 7, 2022   Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)   Conference Call: Dial (646) 960-0369 Conferen

Raises 2022 Financial Guidance Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2022 and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2022 continues to be an outstanding year for Ligand, in particular as royalties from our Pelican Expression Technology platform grow into meaningful revenue contributors," said John Higgins, CEO of Ligand. "The business is enjoying good momentum with numerous positive late-stage de

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) will report second quarter 2022 financial results after the close of the U.S. financial markets on Monday, August 8, 2022 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will include Ligand's CEO John Higgins, President and COO Matt Foehr, and Executive Vice President and CFO Matt Korenberg. Conference Call and Webcast Information What: Ligand conference call to discuss financial results and provide general business updates     Date: Monday, August 8, 2022     Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)     Conference Call:

Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2022 and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2022 is off to a strong start with solid financial performance from our growing roster of royalty-bearing products and great execution from all our core technology platforms," said John Higgins, CEO of Ligand. "We are excited about the potential growth of our business in the years to come as several recently approved pr

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) will report first quarter 2022 financial results after the close of the U.S. financial markets on Wednesday, May 4, 2022 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will include Ligand's CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg. Conference Call and Webcast Information What: Ligand conference call to discuss financial results and provide general business updates   Date: Wednesday, May 4, 2022   Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)   Conference Call: Dial (866) 518

Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and 12 months ended December 31, 2021, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2021 was an outstanding year for Ligand, both operationally and financially. The execution by the team and the performance of the business throughout the past several months position us very well for a transformative 2022. Last year, we had the most substantial calendar of product and market approvals in Lig

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) will report fourth quarter 2021 financial results after the close of the U.S. financial markets on Thursday, February 17, 2022 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will include Ligand's CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg. Conference Call and Webcast Information What: Ligand conference call to discuss financial results and provide general business updates   Date: Thursday, February 17, 2022   Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)   Conference Call

Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2021 and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "Our business has performed exceptionally well over the past few months, and we are pleased to be reporting excellent third quarter financial results," said John Higgins, CEO of Ligand. "Our core royalties tied to Kyprolis and Evomela continue to grow nicely, and we have seen five approvals during the last y

Strategic Decision Based Upon Recent Business Success and Plans to Support Continued Growth and Investments in OmniAb's Drug Discovery Platform Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced it is pursuing plans to split Ligand into two separate, publicly traded companies with one featuring the OmniAb business, and the other featuring Ligand's existing collection of core royalties and the technologies, pipeline and contracts associated with the Pelican protein expression platform and the Captisol business. The spin-off is intended to create two companies with dedicated operational focus, business-specific capital al

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) will report financial results for the three and nine months ended September 30, 2021 after the close of the U.S. financial markets on Tuesday, November 9, 2021 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will include Ligand's CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg. Conference Call and Webcast Information What: Ligand conference call to discuss third quarter 2021 financial results and provide general business updates     Date: Tuesday, November 9, 2021     Time: 4:30 p.m. Eastern t

Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2021 and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "This is shaping up to be an outstanding year for Ligand with solid financial performance and great progress with all of our core technology platforms," said John Higgins, Chief Executive Officer of Ligand. "We are very pleased to report a smooth and efficient integration of the four acquisitions we completed last